Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).
More than a decade ago, radiation oncologists noticed a nifty phenomenon: Sometimes radiation used locally against a tumor could excite the immune system to attack cancer systemically throughout the body.
HPV vaccination rates in populations at high-risk of contracting HIV are particularly low, increasing the risk of HPV and HIV co-infection.
A potential new immune-based therapy to treat precancers in the cervix completely eliminated both the lesion and the underlying HPV infection in a third of women enrolled in a clinical trial.
Tobacco use causes a field of precancerous cells, increasing the risk of developing head & neck cancer. But exactly how this precancerous field influences cancer has been often overlooked.
Researchers have started pilot clinical studies in head and neck cancer patients to determine if Raman spectroscopy, a noninvasive imaging technique, can effectively spare some patients of the toxic side effects of ineffective radiation therapy.
A new Johns Hopkins study offers promise towards someday being able to non-invasively examine changes in cancerous tumors to determine whether they'll respond to radiation treatment, before treatment even begins.
Scaling up the human papillomavirus (HPV) vaccine could eradicate cervical cancer in high-income countries within 30 years, according to a new study.
Regular use of aspirin or other nonsteroidal anti-inflammatory drugs may help some patients with head and neck cancer survive the disease, according to a study led by Professor Jennifer Grandis at the University of California, San Francisco.
Regular use of a common type of medication, such as aspirin and ibuprofen, significantly improves survival for a third or more patients with head and neck cancer, a new study led by UC San Francisco has found.
Cancer patients are often prescribed pain medications, for example during recovery from surgical procedures. However, for many cancer patients, the use of opioid pain medications during treatment can be a gateway to misuse or addiction once treatment ends.
AIDS patients suffer higher rates of cancer because they have fewer T-cells in their bodies to fight disease. But new research examines why HIV-infected patients have higher rates of cancer--among the leading causes of death among that population--than the general population.
The Head and Neck Cancer Foundation is calling all Brits to ask their dentists to conduct mouth cancer screens at their next appointment. This should be routinely included within the price of a dental check-up and should take no more than one minute.
NEC Corporation and Transgene today announced the signing of a Memorandum of Understanding for a strategic collaboration aimed at the treatment of solid cancers.
Despite improved survival rates among cancer patients, the risk of death by suicide remains high, especially among those treated for head and neck cancers.
A new blood test developed by University of North Carolina Lineberger Comprehensive Cancer Center researchers shows promise for tracking HPV-linked head and neck cancer patients to ensure they remain cancer-free after treatment.
Immunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer, according to surprising new data from a major phase III clinical trial.
Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasized, according to late-breaking results from the KEYNOTE-048 study reported at the ESMO 2018 Congress in Munich.
Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.
Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).
Researchers at La Jolla Institute for Immunology and UC San Diego have been awarded $ 4.5 million as part of the National Cancer Institute's Cancer Moonshot initiative.